OGEN - Oragenics comes up empty in pursuit BARDA funding for COVID-19 vaccine

Nano cap Oragenics (OGEN) reports that the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority ((BARDA)) has decided to pass on funding the development of COVID-19 vaccine candidate Terra CoV-2.The company says its will "continue to pursue" other sources if non-dilutive funding, grants and corporate partnerships, but an equity capital raise remains an option to advance development.It acquired a non-exclusive license to NIH's stabilized pre-fusion Terra CoV-2 spike protein in March.Shares are currently suspended from trading.

For further details see:

Oragenics comes up empty in pursuit BARDA funding for COVID-19 vaccine